The invention relates to a pharmaceutical composition comprising 5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide, referred to herein as ‘Compound A’, or a pharmaceutically acceptable salt thereof, and a cyclodextrin. More specifically, the invention relates to a solid pharmaceutical composition comprising Compound A and a cyclodextrin, and a pharmaceutical composition for parenteral administration prepared by dissolving this solid pharmaceutical composition. Furthermore, the invention relates to the use of such compositions for the treatment of cancer.本發明係關於醫藥組合物，其包含5-(5-氯-2-{[(3S)-3-(嗎啉-4-基甲基)-3,4-二氫異喹啉-2(1H)-基]-羰基}苯基)-N-(5-氰基-1,2-二甲基-1H-吡咯-3-基)-N-(4-羥基苯基)-1,2-二甲基-1H-吡咯-3-甲醯胺(在本文中稱為「化合物A」)或其醫藥上可接受之鹽，及環糊精。更特定而言，本發明係關於包含化合物A及環糊精之固體醫藥組合物，及藉由溶解此固體醫藥組合物所製備用於非經腸投與之醫藥組合物。此外，本發明係關於該等組合物用於治療癌症之用途。
